Insider trade

Tango Therapeutics (TNGX): 10% owner sold ~$2.56M

Third Rock Ventures IV, 10% owner at Tango Therapeutics, sold ~$2.56M of Tango Therapeutics shares.

~$2.56M
Approx. value · 364K sh @ $7.04
14.4M
Holds after · shares reported
Traded
Sep 16, 2025
Filed
Sep 17, 2025

What stands out in this filing

  • The sale was 2.5% of the shares this insider held before it; the filing reports 14,363,975 shares afterwards.
  • 363,541 shares at an average of $7.04 each, as reported on the form.
  • No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 19, 2025Insider10% owner sold ~$7.71M of TNGX shares in the open market
  2. Aug 22, 2025Insider10% owner sold ~$2.12M of TNGX shares in the open market
  3. Sep 5, 2025Insider10% owner sold ~$4.5M of TNGX shares in the open market
  4. Sep 8, 2025Insider10% owner sold ~$609K of TNGX shares in the open market
  5. Sep 16, 2025 · this disclosureInsider10% owner sold ~$2.56M of TNGX shares in the open market

What came next

  1. Sep 25, 2025Insider10% owner sold ~$4.01M of TNGX shares in the open market
  2. Oct 23, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  3. Oct 23, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  4. Nov 4, 2025Company filing · Form 8-K · ResultsReported its results
  5. Nov 18, 2025Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement
  6. Jan 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 2, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to eight (8).”
  7. Jan 7, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On January 7, 2026, Barbara Weber, M.D. notified the board of directors (the “Board”) of the Company of her retirement and resignation as President and Chief Executive Officer of the Company, in each case, effective as of January 8, 2026 (the “Effective Date”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tango Therapeutics

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TNGX page.

Other recent filings by Third Rock Ventures IV, L.P., 10% owner

The full history of Third Rock Ventures IV, L.P., 10% owner is on the profile page.

How this filing works

Explore the data

Common questions

Which Tango Therapeutics (TNGX) insider traded, and how much?

Third Rock Ventures IV, 10% owner at Tango Therapeutics, sold ~$2.56M of Tango Therapeutics shares. 364K shares at $7.04.

When did it happen, and when was it made public?

Traded: Sep 16, 2025. Filed: Sep 17, 2025. That is 1 day between the two dates.

What stands out in this filing?

The sale was 2.5% of the shares this insider held before it; the filing reports 14,363,975 shares afterwards. 363,541 shares at an average of $7.04 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Tango Therapeutics recently?

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the TNGX page.

Does this mean TNGX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tango Therapeutics

Everything OQRO holds on this company is on its TNGX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data